Featured Companies - ChinaBio® Today

Recent Articles

Steve Yang: AstraZeneca in China Wants to Transform Pharma R&D Models Feb 3, 2012: Steve Yang, AstraZeneca’s high profile VP and Head of R&D for Asian and Emerging Markets, is setting an ambitious goal for the company’s China R&D operation: “We will try to innovate and transform how we do R&D,” said Yang in a McKinsey Quarterly interview. Because innovative pharma development is still new in China, “we are starting with a clean slate,” he added. “But that could be an opportunity,” given that established ways of doing drug R&D are not institutionalized, leaving China free to map its own path. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:

For Saladax Biomedical, China Could Be the Largest Market Jan 27, 2012: Saladax Biomedical, a Bethlehem, Pennsylvania medical diagnostic reagent developer and manufacturer, believes China will be a big part of the company’s future. Edward L. Erickson, CEO of Saladax, told ChinaBio® Today in an exclusive interview, “The volume of the market in China for our products appears to be larger than the US and Europe put together.” Saladax makes MyCare™ therapeutic dose management products, and its major product is currently My5-FU™, a dose management test for 5-FU chemotherapy. More details....

Share this with colleagues:

SuperNova Developing Point of Care Diagnostics Technology Jan 24, 2012: SuperNova Diagnostics®, a US-based, global diagnostics company with deep China connections, is developing a point of care platform based on LCD technology. The device combines ease of use with low cost – a seemingly unbeatable combination. And it is now moving toward production. “It’s going to be a good year for Supernova Diagnostics,” said Neil Campbell, CEO and Co-Founder of the company in an exclusive ChinaBio® Today interview. “There aren’t a lot of technologies out there that can do what we do.” More details....

Share this with colleagues:

China Scientists Given US Award for Cancer Breakthrough Jan 20, 2012: Two China scientists have been awarded a prestigious US prize for their groundbreaking work with a form of leukemia. By combining traditional Chinese medicine and western approaches, they increased the five-year survival rate of acute promyelocytic leukemia (APL) from 25% to an astonishing 95%. In recognition of their contribution, Drs. Zhen-Yi Wang and Zhu Chen were named recipients of the 7th Szent-Györgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research in the US. More details....

Share this with colleagues:

ASLAN Pharma – A Very Focused Business Plan Nov 17, 2011: Two years ago, Carl Firth, PhD, MBA, was scrutinizing the possibilities implicit in Asia’s drug development scene. That led Firth to a very non-rhetorical question: “What can we do to leverage all these high quality assets?” he asked. The answer to that question is ASLAN Pharmaceuticals, a Singapore-based drug development startup with a virtual business model. In its first 18 months, ASLAN has completed its first round of fund raising, in-licensed two drug candidates, and Dr. Firth told ChinaBio® Today in an exclusive interview that a third deal will be announced soon. More details....

Novo Nordisk Rejects China M&A; Will Grow through Innovation Nov 2, 2011: Novo Nordisk A/S , the Danish pharma that specializes in diabetes drugs, does not want to grow in China through M&A. It plans to continue its emphasis on developing its own innovative drugs. To that end, Novo Nordisk has previously announced investments in its Beijing R&D center and Tianjin manufacturing plant, while it is also working to increase diabetes education in China. More details....

Stock Symbol: (NYSE: NVO) Share this with colleagues:

Roche’s Strategy for China – Global, Not Local Oct 30, 2011: When asked to describe Roche’s strategy for China, Dr. Joe McCracken, Global Head of Business Development for the Swiss pharma, disarmingly answered “We don’t have one.” But he didn’t mean Roche has no strategy for China. “China is part of our global strategy and everything China does is related to our global strategy,” he explained in an exclusive interview with ChinaBio® Today in Shanghai. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:

Sinovac Lands Flu Vaccine Order from Beijing CDC Oct 13, 2011: Sinovac Biotech was selected by the Beijing CDC as one of the four manufacturers to supply two million doses of seasonal influenza vaccine. The actual amount shipped will depend upon demand. Sinovac needs some good news. Its sales declined from a high-water mark of $84 million in 2009, the year of the swine flu outbreak, to just $33 million in 2010. Profits fell from $20 million two years ago to a loss of $8.5 million last year. Fortunately, Sinovac has $92.7 million in cash to fall back on. More details....

Stock Symbol: (NSDQ: SVA) Share this with colleagues:

SciClone Announces $20 Million Stock Buyback Oct 5, 2011: SciClone Pharma announced a share repurchase program of up to $20 million over the next 24 months. SciClone, headquartered in California, commercializes and markets Western drugs in China. In addition to boosting the company’s stock price, the repurchase program will partially offset the 8.3 million shares that may be offered by the previous owners of NovaMed, which SciClone acquired in April of this year. Despite its solid financial performance, SciClone's stock price remains low. More details....

Stock Symbol: (NSDQ: SCLN)

GSK Seeking Up to $2B Bolt-on Acquisitions in India Oct 4, 2011: GlaxoSmithKline is looking to complete “smaller” acquisition targets in India in the $500 million to $2 billion range, according to the company’s CEO Andrew Witty. He characterized these transactions as bolt-on additions rather than transformative ones. GSK does not need a large acquisition, he said, because the company already has a well-established presence in India with a recognizable brand name. His comments would seem to apply equally to China, where GSK has been involved in several "smaller" M&A transactions. More details....

Stock Symbol: (NYSE: GSK) Share this with colleagues: